Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Hepatocyte growth factor is a reliable marker for efficient anti-bacterial therapy within the first day of treatment
Linköping University, Department of Clinical and Experimental Medicine, Division of Microbiology and Molecular Medicine. Linköping University, Faculty of Health Sciences. PEAS Institute, Linköping.
Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart and Medicine Center, Department of Clinical Physiology in Linköping.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart and Medicine Center, Department of Nephrology.
Kalmar County Hospital, Sweden.
Show others and affiliations
2014 (English)In: Advances in Bioscience and Biotechnology, ISSN 2156-8456, E-ISSN 2156-8502, Vol. 5, no 10, 823-830 p.Article in journal (Refereed) Published
Abstract [en]

Rapid diagnosis and choice of appropriate antibiotic treatment might be life-saving in serious infectious diseases. Still the available markers that can evaluate and monitor the diagnosis and treatment are few. Hepatocyte growth factor (HGF) has been studied as a potent regenerative factor produced and released during injuries such as infectious diseases. Monitoring of HGF levels might predict therapy results better than C-reactive protein (CRP) within the first day of treatment in pneumonia. For further investigation of previous observations we aimed to study HGF as a first-day marker in over-representing infectious diseases in comparison to procalcitonin (PCT), CRP and body temperature. Fifty-one patients with community acquired infectious diseases were included consequently at admittance and the serum samples were collected before and within 18 - 24 hours of treatment. HGF levels decreased significantly in case of efficient antibiotic therapy and HGF was shown to be better than PCT, CRP and body temperature to evaluate treatment. In patients with pneumonia, monitoring of HGF was most reasonable. HGF might be used as a therapeutic marker within the first day of empiric antibiotic treatment during infection.

Place, publisher, year, edition, pages
Scientific Research Publishing, 2014. Vol. 5, no 10, 823-830 p.
Keyword [en]
Hepatocyte Growth Factor, C-Reactive Protein, Procalcitonin, Temperature, Antibacterial Therapy
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-110998DOI: 10.4236/abb.2014.510096OAI: oai:DiVA.org:liu-110998DiVA: diva2:751877
Available from: 2014-10-02 Created: 2014-10-02 Last updated: 2015-08-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Brudin, LarsAlmroth, GabrielNayeri, Fariba
By organisation
Division of Microbiology and Molecular MedicineFaculty of Health SciencesDivision of Cardiovascular MedicineDepartment of Clinical Physiology in LinköpingDivision of Drug ResearchDepartment of NephrologyDepartment of Infectious Diseases
In the same journal
Advances in Bioscience and Biotechnology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 554 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf